A novel cooled laser focal therapy device demonstrates 84% treatment success for localized prostate cancer at 3 months, with only 12% reporting erectile dysfunction and minimal impact on urinary ...

An NHS trial over 10 years followed nearly 3,500 men who received focal therapy, a less invasive treatment.

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...

Investigators who conducted 2 clinical trials concluded that focal therapy is not inferior to radical prostatectomy with respect to treatment failure. Focal therapy such as high-intensity focused ...

Localized prostate cancer treatments include radical prostatectomy and focal therapy, with the latter targeting only cancerous areas to preserve healthy tissue. Focal therapy allows for active ...

In a trial, the ProFocal device for intermediate-risk prostate tumor ablation had an 84% treatment success rate with low morbidity. Cooled laser focal therapy ablation using a novel device (ProFocal®; ...

TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

A five-year study on men that had just the cancerous portion of their prostate glands destroyed shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual ...